IP
PPH icon

Intellectus Partners’s VanEck Pharmaceutical ETF PPH Stock Holding History

Intellectus Partners’s Portfolio PPH Stock Details PPH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q1 		– Sell
-350
Closed -$18K – 716
2016
Q4 		$18K Buy
+350
New +$18.7K 0.01% 467

Other funds holding PPH

Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
Citigroup
Citigroup New York $303B AUM 53.02% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
RJA
Raymond James & Associates St Petersburg, Florida $164B AUM 33.91% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
SCM
Stuyvesant Capital Management Armonk, New York $41.1M AUM 17.11% 1-Year Est. Return
CC
Colrain Capital Boston, Massachusetts $295M AUM 82.72% 1-Year Est. Return
LPL Financial
LPL Financial San Diego, California $445B AUM 25.58% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return

Intellectus Partners's PPH Position: Q1 2017 in Review

Intellectus Partners sold out of VanEck Pharmaceutical ETF (PPH) in Q1 2017, closing a stake of 350 shares — an estimated $18K sold.

Intellectus Partners first reported a position in PPH in Q4 2016 and held it in 1 quarter. The position peaked at $18K in Q4 2016. 50 funds tracked by Wall St. Rank hold PPH as of Q1 2017.

  • Intellectus Partners reported no remaining VanEck Pharmaceutical ETF position as of Q1 2017 after selling out during the quarter.
  • Intellectus Partners sold 350 VanEck Pharmaceutical ETF shares in Q1 2017, an estimated $18K.
  • Intellectus Partners first reported a position in VanEck Pharmaceutical ETF in Q4 2016 and held it in 1 quarter.
  • Intellectus Partners's VanEck Pharmaceutical ETF position peaked at $18K in Q4 2016.
  • 50 funds tracked by Wall St. Rank held VanEck Pharmaceutical ETF as of Q1 2017.

Based on Intellectus Partners's 13F filing for Q1 2017, filed 8 May 2017.